UK's ABPI lists team to negotiate value-based pricing contract
The Association of the British Pharmaceutical Industry (ABPI) on Wednesday announced the team which will negotiate the most radical changes to the way the country pays for its drugs in decades.
In a statement the industry group listed five negotiators who will sit opposite government representatives to thrash out how the new value-based drug pricing (VBP)/Pharmaceutical Price Regulation Scheme (PPRS) contracts will work.
John Kearney, UK & Ireland general manager of Amgen, who will chair the team.
Erik van Snippenberg, general manager & senior vice-president GlaxoSmithKline UK
Jon Emms, managing director of Pfizer UK
Matthew Speers, managing director, for UCB across British and Irish Isles.
Pete Butterfield, executive director, Alliance.
They will be supported by an ABPI team led by the association's commercial director, Alison Clough, according to the ABPI statement.
In a joint statement on Friday the ABPI and Department of Health issued limited information on how they expect the new VBP/PPRS contracts to work.
History suggests the new PPRS contract will change at least slightly from its predecessors although the broad approach is well established. It is expected to cover the 'vast majority' of drugs available in the UK.
VBP is an entirely new route to pricing drugs and initial use, at least, is likely to be limited to new active substances coming on the market from January 1 2014 when the new contracts take force.